Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Erythropoietic protoporphyria (EPP) is a rare disease in which patients experience severe light sensitivity. It is caused by a deficiency of ferrochelatase (FECH), the last enzyme in heme biosynthesis (HBS). The lack of FECH causes accumulation of its photoreactive substrate protoporphyrin IX (PPIX) in patients' erythrocytes. Here, we explored an approach for the treatment of EPP by decreasing PPIX synthesis using small-molecule inhibitors directed to factors in the HBS pathway. We generated a FECH-knockout clone from K562 erythroleukemia cells, which accumulates PPIX and undergoes oxidative stress upon light exposure. We used these matched cell lines to screen a set of publicly available inhibitors of factors in the HBS pathway. Inhibitors of the glycine transporters GlyT1 and GlyT2 lowered levels of PPIX and markers of oxidative stress selectively in K56211B4 cells, and in primary erythroid cultures from an EPP patient. Our findings open the door to investigation of glycine transport inhibitors for HBS disorders.

Original publication

DOI

10.1016/j.chembiol.2021.02.021

Type

Journal article

Journal

Cell Chem Biol

Publication Date

19/08/2021

Volume

28

Pages

1221 - 1234.e6

Keywords

CRISPR-Cas9, drug repurposing, erythropoietic protoporphyria, glycine transporter 2, oxidative stress, photodamage, protoporphyrin IX, Cells, Cultured, Erythrocytes, Glycine Plasma Membrane Transport Proteins, Humans, K562 Cells, Molecular Structure, Protoporphyria, Erythropoietic, Protoporphyrins